FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bahcall Safi R  (Last) (First) (Middle)  C/O SYNTA PHARMACEUTICALS CORP.  45 HARTWELL AVENUE  (Street)  LEXINGTON MA 02421  (City) (State) (Zip)							2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [ SNTA ]  3. Date of Earliest Transaction (Month/Day/Year) 03/06/2012  4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner  X Officer (give title Other (specify below)  President and CEO  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person				
		Tab	le I - N	on-Deriv	ative S	Sec	urities	Acc	quired, D	isp	osed o	f, or Be	neficiall	y Owned	ı	,			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquir Disposed Of (D) (Instance)			Securiti Benefici Owned	5. Amount of Securities Beneficially Owned Following		: Direct r     ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	nt (A) or (D)		Reporte Transac	Reported Transaction(s) (Instr. 3 and 4)		. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	med on Date, Day/Year)	4. Transact Code (In 8)	tion of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Followins Reported Transacti (Instr. 4)	e Ow s Fo ally Dii or g (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$4.22	03/06/2012			A		185,000		(1)	03	3/06/2022	Common Stock	185,000	\$0	185,00	00	D		

## Explanation of Responses:

1. The option vests as to 25% of the shares on March 6, 2013 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.

/s/ Ann Margaret Eames, Attorney-in-Fact

\*\* Signature of Reporting Person

03/08/2012

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.